Viewing nowCombinationSitagliptin/Metformin Extended-Release Tablets 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Dongwha Pharmaceutical Co., Ltd.

MFDS item code 202201898 · Approved 2022.05.10 · Insurance code 642707290
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication contains both sitagliptin and metformin, which help control blood sugar levels in patients with type 2 diabetes. When used in conjunction with dietary and exercise therapy, it aids in effectively improving blood sugar levels, thereby supporting more stable blood sugar management.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken once daily with a meal, preferably in the evening, and the dose should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: For patients with no prior history of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose is not adequately controlled with sitagliptin monotherapy, the initial dose of this medicine is a total daily dose of sitagliptin 100 mg and metformin 1000 mg. If blood glucose is not adequately controlled with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not switch to this medicine. 2. Patients receiving metformin treatment: - The recommended initial dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is a total daily dose of sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at a dose of 850 mg or 1000 mg twice daily with their current metformin regimen may start with 2 tablets of this medicine 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is a total daily dose of sitagliptin 100 mg; the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustments. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1,000 mg daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.
This medication contains sitagliptin and metformin, and is used for diabetes treatment. However, there are several precautions you should be aware of before taking this medication. First, this medication can cause severe allergic reactions, so if you experience symptoms such as a skin rash, difficulty breathing, or swelling of the face or neck, you should stop taking it immediately and inform your healthcare provider. Second, there is a risk of pancreatitis, which is an inflammation of the pancreas. If you experience abdominal pain, nausea, or vomiting while taking this medication, consult your doctor immediately. Third, due to the metformin component, there can be a rare but serious metabolic disorder known as lactic acidosis. Caution is needed if you have severe dehydration, infections, or heart disease. Fourth, this medication should not be taken by patients with decreased kidney function, acute heart conditions, severe infections, or dehydration, and its use should be discontinued for a period before and after surgery. Fifth, it is safe to avoid this medication for women who are pregnant or may become pregnant, as well as nursing mothers. Sixth, during the use of this medication, regular monitoring of kidney function and blood tests should be conducted, and it is recommended to periodically check vitamin B12 levels. Seventh, if taken with other hypoglycemic agents or insulin, there is a risk of hypoglycemia, so pay attention to symptoms and adjust medication dosages if necessary. Eighth, alcohol consumption can increase the risk of lactic acidosis, so excessive drinking should be avoided while taking this medication. Lastly, this medication's safety and efficacy have not been established in children under 18 years of age, so it is advisable not to use it in this population. When taking this medication, be sure to understand these precautions, and consult with your healthcare provider if any abnormal symptoms arise.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture from entering. It is safe to store it at room temperature between 1 and 30 degrees Celsius. Storing it this way will help maintain its effectiveness for a longer period.
Bright green, oval-shaped extended-release film-coated tablet, convex on both sides
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Dongwha Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.